Personalised Cancer Medicine Flashcards 2022

Indications determined by the organ of origin
Lung Cancer
Lung Cancer

Standard

Recommended

Currently not recommended
  • EGFR
  • ALK
  • ROS1
  • PDL-1
  • RET*
  • NTRK*
  • KRAS y MET*
  • BRAF V600
  • NGS**
  • HER2
  • NRG1
* in tumors lacking driver mutations
** in biopsies with little sample; Approved in the USA as accompanying diagnosis of EGFR and ALK inhibitors
Download table
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.

References:

1. Garrido P, Conde E, de Castro J, et al. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020 Jul;22(7):989-1003. doi: 10.1007/s12094-019-02218-4.

2. Colomer R, Mondejar R, Romero-Laorden N et al,. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine. 2020 Jul 31;25:100487. doi: 10.1016/j.eclinm.2020.100487.

3. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 Nov;31(11):1491-1505. doi: 10.1016/j.annonc.2020.07.014.

4. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006A.pdf